Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q3 EPS of ($0.07), $0.01 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $159 thousand versus the consensus estimate of $180 thousand.

Earnings